WRAIR Vaccine Production Facility
Abstract
The WRAIR Vaccine Pilot Bioproduction Facility (PBF) will focus on the manufacture of early phase clinical materials for vaccine production from varied platforms, such as live virus, conjugates, recombinant proteins, DNA, and monoclonal antibody approaches that: (a) expand collaborative partnerships for product development that meet DoD requirements; (b) open active intramural-based discovery efforts of new products for development; and (c) initiate and extend strategic partnerships with external collaborators (Government and industry) to develop/co-develop potential new biologic approaches to pandemic disease preparedness.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2022
- Source ID
- 9b238b275a8a83ee5cbcacd9eeb4fa71